[Relation between arterial hypertension and plasma lipoproteins: the Australian experience].
In clinical trials the most frequently used anti-hypertensive treatments have been found to produce unfavourable changes in plasma high-density cholesterol-lipoprotein (HDL-cholesterol) levels. We have investigated whether such effects could be observed in a general population in which these drugs are often prescribed. This population was divided into three groups: subjects with normal blood pressure, subjects with unrecognized arterial hypertension and subjects receiving an anti-hypertensive treatment. Treatment with beta-blockers of obese hypertensive patients was attended by unfavourable changes identical with those observed in a general population under the most common anti-hypertensive therapy.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects*; D001315:Australia; D008076:Cholesterol, HDL / Q000097:blood*; D003327:Coronary Disease / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D011159:Population Surveillance; D012306:Risk
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D008076:Cholesterol, HDL
Relations HTA lipoprotéines plasmatiques: l'expérience australienne.